triamcinolone acetonide + anti-VEGF (CLS-1003) / Clearside Biomedical  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
triamcinolone acetonide + anti-VEGF (CLS-1003) / Clearside Biomedical
TANZANITE, NCT02303184: Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Completed
2
46
US
4 mg CLS-TA, Sham, suprachoroidal sham, IVT aflibercept, Eylea
Clearside Biomedical, Inc.
Macular Edema, Retinal Vein Occlusion
03/16
03/16
NCT03126786: Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

Completed
2
71
US
IVT aflibercept, Eylea, Sham SC, suprachoroidal sham, SC CLS-TA, Triamcinolone Acetonide
Clearside Biomedical, Inc.
Diabetic Macular Edema
04/18
04/18
The HULK Trial, NCT02944240: Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for DME

Not yet recruiting
1/2
20
US
SC CLS-TA, IVT Aflibercept, Eylea
Greater Houston Retina Research, Clearside Biomedical, Inc.
Diabetic Macular Edema
09/17
 
NCT02949024: Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

Completed
1/2
20
US
IVT Aflibercept, Aflibercept, SC CLS-TA, Triamcinolone Acetonide
Clearside Biomedical, Inc.
Diabetic Macular Edema
10/17
10/17

Download Options